Viscira, a leading provider of interactive, new-media and technology solutions for the life sciences industry, continued its stellar business performance into the first quarter of 2012. The company realized an 80 percent increase in revenue for Q1 2012 versus the same period in 2011. This accelerated growth follows on the heels of an increase of more than 65 percent in annual gross revenue for FY 2011 over the prior fiscal year based on the company’s final accounting results.
During the first quarter, Viscira added several new clients, including Otsuka Pharmaceuticals and Teva Pharmaceuticals, to its already impressive client list of life sciences customers. The company also increased its volume of business with existing clients such as Genentech, Roche, Johnson & Johnson, Bristol-Myers Squibb and Novartis.
To satisfy this growing demand, the company continues to aggressively recruit talented professionals across multiple functional areas. Viscira is also exploring options to expand its office infrastructure both at its headquarters location in San Francisco and in New York.
“We are very pleased that we have been able to carry our business momentum forward from last year into 2012,” explains Dave Gulezian, President & CEO of Viscira. “We are passionate about the innovative technology solutions we are delivering, and will work to sustain these strong operating results throughout the year.”
Viscira’s growth has been driven by increasing demand across the company’s portfolio of interactive products and software platforms from next-generation, 3D mechanism of action animations to enhanced KOL video presentation modules to its robust online Interactive Presentation Builder (IPB) solution. Viscira also expects demand for the company’s distinctive iPad applications for the industry to continue to grow significantly through the remainder of 2012 and into the foreseeable future.